ETNB

8.53

3.27% +0.27

시간 외 거래: 8.53

89bio Inc (ETNB)

개요 뉴스 가격 이력 옵션 체인 ETNB 왜 하락? 토론 예측

전일 마감가:

$8.26

열려 있는:

$8.35

하루 거래량:

572.63K

시가총액:

$812.27M

수익:

순이익/손실:

$-142.19M

주가수익비율:

-4.0427

EPS:

-2.11

순현금흐름:

$-129.19M

1주 성능:

-8.38%

1개월 성능:

-26.72%

6개월 성능:

+27.31%

1년 성능:

-46.62%

1일 변동 폭

$8.3499

$8.66

52주 변동 폭

$6.575

$22.93

89bio Inc Stock (ETNB) Company Profile

명칭

89bio Inc

부문

Healthcare (1191)

산업

Biotechnology (687)

전화

415 500 4614

주소

142 Sansome Street, Second Floor, San Francisco, CA

직원

트위터

다음 수익 날짜

2024-05-02

최신 SEC 제출 서류

ETNB's Discussions on Twitter

89bio Inc Stock (ETNB) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2022-05-12	업그레이드	Raymond James	Outperform → Strong Buy
2021-12-20	개시	H.C. Wainwright	Buy
2021-10-26	재개	Cantor Fitzgerald	Overweight
2021-07-29	재개	BTIG Research	Buy
2021-05-25	다운그레이드	Raymond James	Strong Buy → Outperform
2021-04-21	개시	Cantor Fitzgerald	Overweight
2020-10-19	개시	Raymond James	Strong Buy
2020-09-25	업그레이드	BofA Securities	Neutral → Buy
2020-07-31	개시	Piper Sandler	Overweight
2020-07-23	개시	BTIG Research	Buy
2020-07-07	개시	Chardan Capital Markets	Buy
2019-12-09	개시	BofA/Merrill	Neutral
2019-12-09	개시	Oppenheimer	Outperform
2019-12-09	개시	RBC Capital Mkts	Outperform
2019-12-09	개시	SVB Leerink	Outperform

모두보기

89bio Inc 주식(ETNB)의 최신 뉴스

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

GlobeNewswire Inc.

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

GlobeNewswire Inc.

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

The Motley Fool

Madrigal’s stock surges as FDA approves first drug for liver disease MASH

MarketWatch

Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH

MarketWatch

89bio Inc (ETNB) 재무 분석

89bio Inc (ETNB) 순이익 2024

ETNB은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -142.19M 달러로 보고했으며, 전년대비 -39.37% 감소했습니다.

89bio Inc (ETNB) 현금흐름 2024

2023-12-31 종료 분기에 ETNB은 현금흐름(지난 12개월)으로 -129.19M 달러를 기록했으며, 전년 대비 -59.30% 감소했습니다.

89bio Inc (ETNB) 주당 순이익 2024

ETNB이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -2.01달러이며, 전년 대비 +43.22% 성장했습니다.

89bio Inc 주식 (ETNB) 내부자 거래

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Option Exercise	1.93	25,000	48,250	511,889
PALEKAR ROHAN	Chief Executive Officer	Apr 01 '24	Sale	10.91	52,718	575,153	459,171
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 04 '24	Buy	15.35	1,350,000	20,722,500	12,431,584
PALEKAR ROHAN	Chief Executive Officer	Feb 26 '24	Sale	10.76	4,477	48,173	486,889
PALEKAR ROHAN	Chief Executive Officer	Dec 29 '23	Option Exercise	1.93	50,000	96,500	351,225
PALEKAR ROHAN	Chief Executive Officer	Dec 29 '23	Sale	11.20	50,000	560,000	301,225
LAPORTE KATHLEEN	Director	Jul 17 '23	Option Exercise	2.64	12,500	33,000	12,500
LAPORTE KATHLEEN	Director	Jul 17 '23	Sale	18.80	12,500	235,000	0
PALEKAR ROHAN	Chief Executive Officer	Jun 05 '23	Option Exercise	1.93	15,000	28,950	301,978
PALEKAR ROHAN	Chief Executive Officer	Jun 05 '23	Sale	20.00	15,000	300,000	286,978